Russia’s Sputnik V vaccine shows 92% efficacy in phase III Covid-19 trials

This article was originally published here

The interim analysis showed that Sputnik V vaccine has shown an efficacy rate of 92% after the second dose in the patients. Sputnik V vaccine is based on

The post Russia’s Sputnik V vaccine shows 92% efficacy in phase III Covid-19 trials appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply